Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

2020-01-22 12:13:01 | BioPortfolio


This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared to the standard treatment (clopidogrel plus aspirin) in patients with critical limb ischemia undergoing infrapopliteal arterial endovascular intervention.


This study is a multicentre, parallel-group, prospective, randomized open-label, blinded-endpoint adjudication, proof-of-concept, and exploratory trial. Two hundred patients will be randomized in a 1:1 ratio, 72 hours after successful infrapopliteal angioplasty for critical limb ischemia. In the study group, patients will receive oral apixaban 2.5mg twice daily plus aspirin 100 mg once-daily for 12 months. In the control group, aspirin 100 mg once-daily will be taken for 1 year on a background of clopidogrel (75mg daily) for the first three months. The primary endpoint is the composite of target lesion revascularization (TLR), major amputation or restenosis/occlusion (RAS) plus MACE (myocardial infarction, stroke, and cardiovascular death) at 12 months. The primary safety endpoint is the composite of major bleeding and clinically relevant non-major bleeding at 12 months.

Study Design


Critical Limb Ischemia


Apixaban, ASA, Clopidogrel 75mg


IAMSPE - Sao Paulo Public Servants Hospital
São Paulo




Science Valley Research Institute

Results (where available)

View Results


Published on BioPortfolio: 2020-01-22T12:13:01-0500

Clinical Trials [1547 Associated Clinical Trials listed on BioPortfolio]

BEST-Registry (vCLI) -Critical Limb Ischemia

For subjects with critical limb ischemia, identify patient, physician/hospital, and geographic factors associated with variations in treatment strategies; compare treatments and outcomes, ...

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

The purpose of this study is to evaluate whether intramuscular injections of VM202 into the calf is safe and effective in the treatment of critical limb ischemia.

Registry of First-line Treatments in Patients With Critical Limb Ischemia

The principal research question is which treatment modality between open surgical, endovascular and conservative therapy is the most effective in terms of limb salvage, survival and reinte...

Safety Study of Gene Therapy in Treating Lower Leg Ischemia

The purpose of this study is to determine the safety, tolerability and preliminary efficacy of intramuscular injections of VM202 for subjects with critical limb ischemia. Subjects selecte...

Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System

This is a prospective, double-blinded, randomized, placebo-controlled, multi-center, pivotal clinical study in which subjects are evaluated for prevention of major limb amputation in the t...

PubMed Articles [7018 Associated PubMed Articles listed on BioPortfolio]

Kissing-balloon technique for infrapopliteal angioplasty in patients with critical limb ischemia.

This study aimed to analyze the technical aspects and follow-up findings regarding patients with critical limb ischemia who underwent the kissing-balloon technique (KBT).

Notable Racial and Ethnic Disparities Persist in Lower Extremity Amputations for Critical Limb Ischemia and Infection.

The purpose of this study is to investigate the current disparities for major lower extremity amputation in patients with critical limb ischemia (CLI) and infection.

Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage After Infrapopliteal Interventions for Critical Limb Ischemia.

Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) reduce the risk of cardiovascular events and mortality in patients with peripheral arterial disease (PAD). Howe...

Vein Harvest Wound Healing After Bypass Surgery for Critical Limb Ischemia.

Lower limb revascularization surgery, especially when performed using the great saphenous vein (GSV), predisposes patients to major surgical trauma on initially ischemic tissue. Vein harvest wounds (V...

Current Treatment Options in Acute Limb Ischemia.

 Acute limb ischemia represents a clinical emergency with eventual limb loss and life-threatening consequences. It is characterized by a sudden decrease in limb perfusion. Acute ischemia is defined ...

Medical and Biotech [MESH] Definitions

An alternative to amputation in patients with neoplasms, ischemia, fractures, and other limb-threatening conditions. Generally, sophisticated surgical procedures such as vascular surgery and reconstruction are used to salvage diseased limbs.

Distinct regions of mesenchymal outgrowth at both flanks of an embryo during the SOMITE period. Limb buds, covered by ECTODERM, give rise to forelimb, hindlimb, and eventual functional limb structures. Limb bud cultures are used to study CELL DIFFERENTIATION; ORGANOGENESIS; and MORPHOGENESIS.

A zinc finger transcription factor that contains five CYS2-HIS2 ZINC FINGERS and binds to the GLI consensus sequence 5'-GGGTGGTC-3'. The full-length protein functions as a transcriptional activator whereas the truncated C-terminal form functions as a transcriptional repressor of the Sonic Hedgehog (Shh) signaling pathway; a balance between these two forms is critical for limb and digit development. GLI3 also plays a critical role in the differentiation and proliferation of CHONDROCYTES.

Perception of painful and nonpainful phantom sensations that occur following the complete or partial loss of a limb. The majority of individuals with an amputated extremity will experience the impression that the limb is still present, and in many cases, painful. (From Neurol Clin 1998 Nov;16(4):919-36; Brain 1998 Sep;121(Pt 9):1603-30)

An apraxia characterized by the affected limb having involuntary, autonomous, and purposeful behaviors that are perceived as being controlled by an external force. Often the affected limb interferes with the actions of the normal limb. Symptoms develop from lesions in the CORPUS CALLOSUM or medial frontal cortex, stroke, infarction, and neurodegenerative diseases (e.g., CREUTZFELDT-JAKOB SYNDROME, corticobasal degeneration).

More From BioPortfolio on "Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients."

Quick Search

Searches Linking to this Trial